Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
DE000A3CMGM5
Fri, 05.04.2024
APONTIS PHARMA AG
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications
Monheim / Rhein, 5 April 2024. APONTIS PHARMA AG (“APONTIS PHARMA” or the “Company”, Ticker APPH / ISIN DE000A3CMGM5) ha [ … ]
Wed, 08.11.2023
APONTIS PHARMA AG
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA AG with new forecast 2023 and details on announced restructuring program
Monheim am Rhein, 8 November 2023. APONTIS PHARMA AG („Company“, Ticker APPH / ISIN DE000A3CMGM5) today based on the nine-month figures of the current financial year ann [ … ]
Mon, 31.07.2023
APONTIS PHARMA AG
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA: Co-promotion contract with AstraZeneca not to be continued in 2024
Monheim am Rhein, 31 July 2023. APONTIS PHARMA AG („APONTIS PHARMA“ or the „Company“, Ticker APPH / ISIN DE000A3CMGM5) has been informed by AstraZeneca that the co-promotion [ … ]
Mon, 31.07.2023
APONTIS PHARMA AG
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA: Co-promotion contract with AstraZeneca not to be continued in 2024
Monheim am Rhein, 31 July 2023. APONTIS PHARMA AG („APONTIS PHARMA“ or the „Company“, Ticker APPH / ISIN DE000A3CMGM5) has been informed by AstraZeneca that the co-promotion [ … ]
Thu, 27.07.2023
APONTIS PHARMA AG
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026
Monheim am Rhein, 27 July 2023. APONTIS PHARMA AG (“APONTIS PHARMA” or “Company“, Ticker APPH / ISIN DE000A3CMGM5) has withdrawn today its forecast for fiscal year 2 [ … ]
Thu, 27.07.2023
APONTIS PHARMA AG
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026
Monheim am Rhein, 27 July 2023. APONTIS PHARMA AG (“APONTIS PHARMA” or “Company“, Ticker APPH / ISIN DE000A3CMGM5) has withdrawn today its forecast for fiscal year 2 [ … ]
Mon, 10.07.2023
APONTIS PHARMA AG
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA AG: CEO Karlheinz Gast resigns from office for personal reasons
Monheim am Rhein, 10 July 2023. The Chief Executive Officer (CEO) of APONTIS PHARMA AG (“APONTIS PHARMA” or “Company“, Ticker APPH / ISIN DE000A3CMGM5), Karlheinz Gast, has infor [ … ]
Mon, 10.07.2023
APONTIS PHARMA AG
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA AG: CEO Karlheinz Gast resigns from office for personal reasons
Monheim am Rhein, 10 July 2023. The Chief Executive Officer (CEO) of APONTIS PHARMA AG (“APONTIS PHARMA” or “Company“, Ticker APPH / ISIN DE000A3CMGM5), Karlheinz Gast, has infor [ … ]
Tue, 02.05.2023
APONTIS PHARMA AG
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA AG adjusts forecast for fiscal year 2023
Monheim am Rhein, 2 May 2023. APONTIS PHARMA AG (“APONTIS PHARMA” or “Company“, Ticker APPH / ISIN DE000A3CMGM5) adjusts its guidance for fiscal year 2023 as a consequence of delivery difficulties at a [ … ]
Tue, 02.05.2023
APONTIS PHARMA AG
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014APONTIS PHARMA AG adjusts forecast for fiscal year 2023
Monheim am Rhein, 2 May 2023. APONTIS PHARMA AG (“APONTIS PHARMA” or “Company“, Ticker APPH / ISIN DE000A3CMGM5) adjusts its guidance for fiscal year 2023 as a consequence of delivery difficulties at a [ … ]